The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BIOA | -66.25% | N/A | N/A | -59% |
| S&P | +13.96% | +91.24% | +13.85% | +19% |
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Richmond, CA.
The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.
This stock has caught fire after some recent events, but how long will that last?
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.05M | 0.0% |
| Gross Profit | $2.01M | 5376.3% |
| Gross Margin | 97.61% | 0.0% |
| Market Cap | $210.80M | -67.2% |
| Market Cap / Employee | $3.29M | 0.0% |
| Employees | 64 | 0.0% |
| Net Income | -$20.17M | 13.8% |
| EBITDA | -$23.09M | 6.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $215.57M | -35.5% |
| Accounts Receivable | $0.52M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.43M | -38.4% |
| Short Term Debt | $4.71M | -25.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -23.59% | 0.0% |
| Return On Invested Capital | -0.80% | -10.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$16.07M | -5.4% |
| Operating Free Cash Flow | -$16.04M | -7.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.63 | 0.42 | 0.47 | 0.72 | -119.84% |
| Price to Sales | 92.90 | 38.33 | 35.63 | - | |
| Price to Tangible Book Value | 0.63 | 0.42 | 0.47 | 0.72 | -119.84% |
| Enterprise Value to EBITDA | 5.45 | 10.69 | 5.68 | 2.94 | -118.76% |
| Return on Equity | -30.2% | -35.9% | -25.6% | - | |
| Total Debt | $8.70M | $10.31M | $8.75M | $7.13M | -30.16% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
